Search Results
Aug 24, 2026, 01:03 ET Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
combination regimens with incretin-based treatments.In November 2025, Hanmi received IND (Investigational New Drug) clearance from the U.S. FDA (Food and Drug Administration) to initiate a Phase 1 clinical trial of HM17321. The ongoing clinical study is evaluating the safety, tolerability,
More news about: Hanmi Pharm. Co., Ltd.
Aug 24, 2026, 00:40 ET Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
combination regimens with incretin-based treatments.In November 2025, Hanmi received IND (Investigational New Drug) clearance from the U.S. FDA (Food and Drug Administration) to initiate a Phase 1 clinical trial of HM17321. The ongoing clinical study is evaluating the safety, tolerability,
More news about: Hanmi Pharm. Co., Ltd.
Aug 23, 2026, 23:05 ET Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
(PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE), at Henry Ford Hospital in Detroit. Working in close collaboration with Site Principal Investigator
More news about: Pulnovo Medical
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
CD3 (ATG-107 for acute myeloid leukemia).To date, Antengene has obtained 33 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is
More news about: Antengene Corporation Limited
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
pipeline includes ABT-301, a selective HDAC inhibitor in Phase I/II clinical development, and the ABT-500 platform of targeted peptide-drug conjugates and radio-drug conjugates.Laboratory of Veterinary Surgery, The University of TokyoThe Laboratory of Veterinary Surgery, Graduate
More news about: AnBogen Therapeutics
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
pipeline includes ABT-301, a selective HDAC inhibitor in Phase I/II clinical development, and the ABT-500 platform of targeted peptide-drug conjugates and radio-drug conjugates.Laboratory of Veterinary Surgery, The University of TokyoThe Laboratory of Veterinary Surgery, Graduate
More news about: AnBogen Therapeutics
Aug 22, 2026, 13:32 ET Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
action.What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA
More news about: THE ROSEN LAW FIRM, P. A.
Aug 21, 2026, 22:29 ET Global Times: China's economic performance will remain within a reasonable range in H2, meet annual goals
notable technological breakthroughs, including new advances in key and core technologies such as integrated circuits, world-leading progress in innovative drug development, and successful rocket recovery operations both at sea and on land.New growth drivers played a stronger supporting and leading role.
More news about: Global Times
Aug 21, 2026, 22:00 ET Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR
to disclose material information during the Class Period, violating federal securities laws. On July 27, 2026, pre-market, the U.S. Food and Drug Administration ("FDA") published briefing documents ahead of its July 29 advisory committee meeting to review the Biologics License Application ("BLA")
More news about: ClaimsFiler
Aug 21, 2026, 22:00 ET Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
On August 9, 2024, the company announced that the Food and Drug Administration ("FDA") "will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered
More news about: Kahn Swick & Foti, LLC
Aug 21, 2026, 16:20 ET Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action
before the October 5, 2026 deadline.Why Was Replimune Sued? On October 20, 2025, Replimune announced that the U.S. Food and Drug Administration ("FDA") had accepted the resubmission of the Biologics License Application ("BLA") for RP1 in combination with nivolumab for the treatment
More news about: Robbins LLP
Aug 21, 2026, 12:51 ET Regulator and standards body independently agree: one HPLC result isn't enough, Oath Research analysis finds
identity of a research peptide, according to an Oath Research analysis of federal guidance and peer-reviewed standards literature. The U.S. Food and Drug Administration and the U.S. Pharmacopeial Convention's own standards scientists arrive at the same conclusion separately, neither citing the other,
More news about: Oath Research
Aug 21, 2026, 10:15 ET Flow Cytometry Market worth $10.57 billion by 2034 - Exclusive Report by MarketsandMarkets™
expanding as pharmaceutical and biotechnology companies, clinical laboratories, CROs, and academic research institutes increasingly adopt flow cytometry for drug discovery, immunology research, oncology, hematology, cell and gene therapy, and translational studies. Flow cytometry platforms are widely used for
More news about: MarketsandMarkets
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
to submit Investigational New Drug (IND) applications for these candidates in the second half of 2026. By leveraging its robust CMC capabilities, the company is further increasing the probability of success in developing complex molecules, thereby enhancing overall drug developability. In addition, the
More news about: Henlius
Aug 21, 2026, 08:30 ET The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting
Milestone Marks Further Progress in The9's Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately 15% to 16% of the Combined, Nasdaq-Listed CompanySHANGHAI, Aug. 21, 2026 /PRNewswire/
More news about: The9 Limited
Aug 21, 2026, 08:08 ET CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
high quality muscle preservation.Non-CYP metabolism pathway: Hydrolysis-mediated activation avoids CYP450 oxidative metabolism, minimizing drug–drug interaction (DDI) and individual variability;High oral bioavailability: Up to 92% bioavailability with a favorable safety and tolerability
More news about: CureGene
Aug 21, 2026, 08:00 ET Kurt Arnold, Jason Itkin Named 2027 "Lawyer of the Year" as 12 Arnold & Itkin Attorneys Earn Best Lawyers® Recognition
high-profile mass tort cases. In October 2019, the firm won an $8 billion punitive damages verdict against Johnson & Johnson over its antipsychotic drug Risperdal, which the company had marketed to children while withholding data linking it to a hormonal growth disorder in boys; at the time, it was the
More news about: Arnold & Itkin LLP
Aug 21, 2026, 07:45 ET AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
sharedResearch reflects AbbVie's strategy aimed at building a lung cancer pipeline spanning next-generation immunotherapies, targeted antibody-drug conjugates (ADCs) and the potential for novel combination approachesNORTH CHICAGO, Ill.,
More news about: AbbVie
Aug 21, 2026, 05:28 ET China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
framework.This is not equivalent to formal drug marketing approval, but it provides a pathway for personalized therapies to move from clinical research toward practical medical application.In June 2026, construction also began on Likang Life Sciences' new drug R&D and manufacturing center in the
More news about: Likang Life Sciences
Aug 21, 2026, 05:20 ET Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Opamtistomig (LBL-024), the Company's proprietary PD-L1/4-1BB bispecific antibody,
More news about: Nanjing Leads Biolabs Co., Ltd.
Aug 21, 2026, 04:33 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Aug 21, 2026, 04:03 ET Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
multinational randomized Phase 3 study in treatment naïve patients, the Supplemental New Drug Application (sNDA) of ZEGFROVY as first-line treatment has been submitted to China Center for Drug Evaluation (CDE) and the US Food and Drug Administration (FDA). On July 14, Dizal announced that it entered into an exclusive
More news about: Dizal Pharmaceutical
Aug 21, 2026, 03:24 ET 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
economies. Since the beginning of 2026, three Class 1 innovative drugs have been approved for marketing, and five products have advanced to the New Drug Application stage. The Company has successfully constructed a multi-therapeutic pipeline matrix, further consolidating its global competitiveness and
More news about: 3SBio Inc.
Aug 20, 2026, 23:36 ET Implantica receives FDA approval for RefluxStop® - Opening the U.S. market
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop®, the company's implant-based treatment for gastroesophageal reflux disease
More news about: Implantica
Aug 20, 2026, 23:31 ET Implantica receives FDA approval for RefluxStop® - Opening the U.S. market
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop®, the company's implant-based treatment for gastroesophageal reflux disease
More news about: Implantica